Amnis Corporation

Amnis designs, manufactures and markets leading cell imaging instrumentation for the research and clinical markets. The Company’s flagship product is the ImageStream system, which combines the speed and sensitivity of flow cytometry with the power of high resolution digital microscopy. As the only technology capable of imaging cells at high speed directly in bodily fluids, ImageStream enables unique, non-invasive diagnostic applications. These applications include residual disease detection via high throughput FISH, circulating endothelial cell and tumor cell analysis, and advanced automated hematology based on multi-color phenotyping combined with histochemical staining.

Amnis was founded in 1999 and has generated ~50% annualized revenue growth since inception. The Company holds 32 issued US patents and has 55 pending patents covering applications, subsystems, and the ImageStream architecture for imaging both in flow and on substrates. Amnis is privately held and benefits from a strong investor group that includes MedVenture Associates, Crown Venture Fund, and OrbiMed Capital.

Management Team

Board of Directors